[1] Willis DS, Kennedy C, Kilbride L. Breast cancer screening in women with learning disabilities: current knowledge and considerations[J]. Brit J Learn Disabil, 2008, 36(3):171-184.
[2] Chen WQ, Li H, Sun KX, et al. Analysis of the incidence and death of malignant tumors in China in 2014 [J]. China Cancer, 2018, 27(1):1-14. (in Chinese)
陈万青, 李贺, 孙可欣, 等. 2014 年中国恶性肿瘤发病和死亡分析[J].中国肿瘤, 2018, 27(1):1-14.
[3] DeSantis CE, Ma J, Goding Sauer A, et al. Breast cancer statistics, 2017, racial disparity in mortality by state[J]. CA Cancer J Clin, 2017, 67(6): 439-448.
[4] Holzman LB, Marks RM, Dixit VM. A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein[J]. Mol Cell Biol, 1990, 10(11):5830-5838.
[5] Gale NW,Holland SJ,Valenzuela DM, et al. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis.[J]. Neuron,1996,17(1):9-19.
[6] Pasquale, Elena B. Eph receptors and ephrins in cancer: bidirectional signalling and beyond[J]. Nat Rev Cancer, 2010, 10(3):165-180.
[7] Yang LH, Shan ChG, Xu QR, et al. Relationship and research progress of Smac, XIAP, caspase-3 and tumorgenesis [J]. Hebei Pharmaceutical, 2014(4):583-586. (in Chinese)
杨莉晖, 单春光, 许秋荣,等. Smac、XIAP、caspase-3与肿瘤发生的关系及研究进展[J]. 河北医药, 2014(4):583-586.
[8] Huang Y, Li YJ, Zhang BS, et al. Ephrina1-caspase-3 targeting inhibition of breast cancer cells in vitro [J]. Chinese Journal of Anatomy, 2018, 41(6): 646-649. (in Chinese)
黄煜, 李艳娇, 张本斯, 等. EphrinA1-caspase-3 对乳腺癌细胞的体外靶向性抑制作用[J]. 解剖学杂志, 2018, 41(6): 646-649.
[9] Niu JZh, Wang J. HER2, BRCA1, c-myc in the study of breast cancer [J]. Acta Anatomica Sinica,2000, 31(S1):5-8. (in Chinese)
牛建昭,王健.HER2、BRCA1、c-myc在乳腺癌研究方面的进展[J].解剖学报,2000, 31(S1):5-8.
[10] Mitsiades N, Poulaki V, Kotoula V, et al. Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto’s thyroiditis[J]. J Clin Endocrinol Metab, 1998, 83(6):2199-2203.
[11] Kristiansen G, Winzer KJ, Mayordomo E, et al. CD24 expression is a new prognostic marker in breast cancer[J]. Clin Cancer Res, 2003, 9(13):4906-4913.
[12] Choi YL, Lee SH, Kwon GY, et al. Overexpression of CD24: association with invasiveness in urothelial carcinoma of the bladder[J]. Arch Pathol Lab Med, 2007, 131(2):275-281.
[13] Surowiak P, Materna V, Kaplenko I, et al. Unfavorable prognostic value of CD24 expression in sections from primary and relapsed ovarian cancer tissue[J]. Int J Gynecol Cancer, 2010, 16(2):515-521.
[14] Zhao LM, Zhao Sh, Bi RJ, et al. Expression and significance of caspase-3 and caspase-8 in breast cancer [J]. Chinese Journal of Gerontology, 2017, 37(14):3486-3488. (in Chinese)
赵丽敏, 赵帅, 毕仁杰,等. 乳腺癌组织中caspase-3及caspase-8的表达及意义[J]. 中国老年学杂志, 2017, 37(14):3486-3488.
[15] Kataoka H, Igarashi H, Kanamori M, et al. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer[J]. Cancer Sci, 2004, 95(2):136-141.
[16] Kikawa KD, Vidale DR, Van RE, et al. Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation.[J]. J Biol Chem, 2002, 277(42):39274-39279.
[17] Zhang BS, Li Zh, Yang G, et al. Expression and significance of EphA2 and Ephrin A1 in breast cancer in Dali bai region, yunnan province [J]. Journal of Anatomy, 2017, 40(5):529-534. (in Chinese)
张本斯, 李庄, 杨桂,等. 云南大理白族地区乳腺癌EphA2和Ephrin A1的表达及其意义[J]. 解剖学杂志, 2017, 40(5):529-534.
[18] Zhang BS, Bian SY, Pan Y, et al. Expression of EphA2 and EphrinA1 in breast cancer and their relationship with clinicopathological factors [J]. Chinese Journal of Clinical Anatomy, 2017, 35(1):43-47. (in Chinese)
张本斯, 卞思源, 潘云,等. 乳腺癌EphA2和EphrinA1的表达及与临床病理因素的关系[J]. 中国临床解剖学杂志, 2017, 35(1):43-47.
[19] Xing ZhB, Wang FM, Wang BG, et al. Advances of establishment application of human breast carcinoma model in nude mice [J]. Modern Oncology,2017,25(23):3889-3892. (in Chinese)
邢志博,王凤梅,王炳高,等.人乳腺癌裸鼠移植模型建立与应用进展[J].现代肿瘤医学,2017,25(23):3889-3892.
[20] Guo HR, Wang XY, He Sh, et al. Effect of RNAi targeted silencing on CD105 and Ki67 gene expression in OVCAR3 cells of human ovarian cancer [J]. Acta Anatomica Sinica,2016,47(4):502-506. (in Chinese)
郭海荣,王晓燕,贺帅,等.RNAi靶向沉默对人卵巢癌OVCAR3细胞CD105和Ki67基因表达的影响[J].解剖学报,2016,47(4):502-506.
[21] Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential[J]. Lancet Oncol, 2010, 11(2):174-183.
[22] Tobin NP, Lindstrm LS, Carlson JW, et al. Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients[J]. Mol Oncol, 2014, 8(3):741-752.
[23] Yao LSh, Zhang BG, Meng K, et al. Correlation and clinical significance of expression of Ki67, CXCR4 and TGF- in elderly breast cancer tissues [J]. Journal of Applied Gerontology, 2010, 24(5):383-386. (in Chinese)
姚乐申, 张保国, 孟奎,等. Ki67、CXCR4和TGF-β在老年乳腺癌组织中表达的相关性研究及其临床意义[J]. 实用老年医学, 2010, 24(5):383-386.
[24] Denkert C, Loibl S, Müller BM, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial[J]. Ann Oncol, 2013, 24(11):2786-2793.
[25] Li HZh, Yu K, Wang ZM, et al. relationship between the expression and mutation of related genes in breast cancer [J]. Acta Anatomica Sinica,2003(4):390-394. (in Chinese)
李红智,俞康,王宗敏,谢丽微.乳腺癌细胞动力学指标与相关基因表达、突变的关系[J].解剖学报,2003(4):390-394.
[26] Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential[J]. Lancet Oncol, 2010, 11(2):174-183.
|